Baszucki Group Funds Oxford Psychosis Trial
Analysis based on 6 articles · First reported May 21, 2026 · Last updated May 22, 2026
The funding of this clinical trial by Baszucki Group>>> for the University of Oxford could potentially lead to new, non-pharmacological treatments for psychosis, which would be significant for the healthcare and biotechnology industries. While not directly impacting stock prices immediately, successful trial outcomes could open new market segments for metabolic therapies and attract investment in related research and development.
The Baszucki Group>>> announced a £1.17 million grant to the University of Oxford to fund a randomized controlled trial. This trial, led by Amedeo Minichino>>>, will assess the feasibility, safety, and efficacy of a ketogenic diet for 50 patients (aged 14-35) at clinical high risk of psychosis (CHR-P). The study aims to evaluate the diet's ability to improve mental and physical health, monitor symptom severity, cognitive function, sleep behavior, and physical health, and follow patients for up to three years. This initiative, supported by Jan Ellison Baszucki>>> and co-founded by David Baszucki>>> of Roblox Corporation>>>, builds on growing research into metabolic therapies for serious mental illness and seeks to provide a novel intervention before psychotic onset.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard